Blue Trust Inc. Has $2.63 Million Position in Novo Nordisk A/S (NYSE:NVO)

Blue Trust Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 34.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,567 shares of the company’s stock after acquiring an additional 7,864 shares during the period. Blue Trust Inc.’s holdings in Novo Nordisk A/S were worth $2,629,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the third quarter valued at about $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the third quarter valued at about $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the third quarter worth about $48,000. Finally, M&R Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after acquiring an additional 297 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $87.45 on Tuesday. The stock has a 50-day moving average of $95.35 and a 200-day moving average of $114.80. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $392.43 billion, a PE ratio of 28.30, a P/E/G ratio of 0.90 and a beta of 0.45.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.